Trius Therapeutics announces positive phase II results on TR-701

Trius Therapeutics, Dong-A Pharmaceutical’s U.S. partner announced on June 10 that it gained the positive results from its Phase 2 clinical trial evaluating the safety and efficacy of oral TR-701, its investigational antibiotic for the treatment of severe complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, especially drug-resistant strains such as methicilli...